Physician profile
Donna L Ackerman
NPI 1295728467
$827.26
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $263 · 2022: $14.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $253.81 | 2019-2020 | |
| Pfizer INC. | $162.13 | 2019 | |
| Tris Pharma INC | $88.19 | 2020 | |
| Eisai INC. | $44.27 | 2020 | |
| Shire North American Group INC | $40.39 | 2019 | |
| Genentech USA, INC. | $38.82 | 2020 | |
| Sanofi Pasteur INC. | $38.05 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $37.36 | 2020 | |
| Cranial Technologies, INC | $31.29 | 2019 | |
| Merck Sharp & Dohme LLC | $25.14 | 2019-2020 | |
| Kaleo, INC. | $19.91 | 2020 | |
| Neos Therapeutics, Lp | $19.58 | 2019 | |
| Boston Scientific Corporation | $14.85 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.